OptimizeRx (NASDAQ:OPRX) Given New $14.00 Price Target at JMP Securities

OptimizeRx (NASDAQ:OPRX) had its price target boosted by JMP Securities from $11.00 to $14.00 in a research report report published on Tuesday,Benzinga reports. They currently have a market outperform rating on the stock.

Separately, B. Riley upgraded OptimizeRx to a “strong-buy” rating in a research report on Wednesday, March 12th. Three analysts have rated the stock with a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $10.38.

OptimizeRx Stock Up 19.7%

OPRX opened at $11.01 on Tuesday. The business’s fifty day moving average is $8.35 and its two-hundred day moving average is $6.37. The company has a debt-to-equity ratio of 0.29, a quick ratio of 3.23 and a current ratio of 3.23. The company has a market cap of $203.61 million, a price-to-earnings ratio of -8.28 and a beta of 1.28. OptimizeRx has a one year low of $3.78 and a one year high of $14.13.

OptimizeRx (NASDAQ:OPRX) last issued its quarterly earnings data on Monday, May 12th. The company reported $0.08 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.11) by $0.19. OptimizeRx had a negative return on equity of 4.92% and a negative net margin of 27.41%. The business had revenue of $21.93 million for the quarter, compared to the consensus estimate of $18.69 million. Analysts anticipate that OptimizeRx will post -0.33 EPS for the current fiscal year.

Insider Buying and Selling

In other OptimizeRx news, Director James Paul Lang bought 321,408 shares of OptimizeRx stock in a transaction that occurred on Friday, March 14th. The shares were purchased at an average cost of $7.60 per share, for a total transaction of $2,442,700.80. Following the completion of the transaction, the director now owns 389,452 shares of the company’s stock, valued at $2,959,835.20. This represents a 472.35% increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 6.10% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On OptimizeRx

Several large investors have recently added to or reduced their stakes in OPRX. SBI Securities Co. Ltd. purchased a new position in OptimizeRx during the fourth quarter worth about $25,000. GAMMA Investing LLC purchased a new position in OptimizeRx during the first quarter worth about $33,000. SG Americas Securities LLC purchased a new position in OptimizeRx during the fourth quarter worth about $51,000. Wells Fargo & Company MN lifted its position in OptimizeRx by 33.3% during the fourth quarter. Wells Fargo & Company MN now owns 11,208 shares of the company’s stock worth $54,000 after buying an additional 2,797 shares during the period. Finally, Graham Capital Management L.P. purchased a new position in OptimizeRx during the fourth quarter worth about $81,000. 76.47% of the stock is currently owned by hedge funds and other institutional investors.

About OptimizeRx

OptimizeRx Corporation, a digital health technology company, enables care-focused engagement between life sciences organizations, healthcare providers, and patients at critical junctures throughout the patient care journey. It offers various tech-enabled marketing solutions through its Artificial Intelligence-generated Dynamic Audience and Activation Platform, which enables customers to execute traditional marketing campaigns on its proprietary digital point-of-care network, as well as dynamic marketing campaigns that optimize audiences in real time to increase the value of treatment information for healthcare professionals and patients in response to clinical care events.